Amphastar Shareholders Approve Directors, Auditor and Pay Practices
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Amphastar Pharmaceuticals ( (AMPH) ) just unveiled an update.
At its 2026 annual meeting of stockholders, Amphastar Pharmaceuticals’ investors elected three Class I directors—David Gaugh, William J. Peters, and Jacob Liawatidewi—to serve until the 2029 annual meeting or until successors are chosen, underscoring continuity in the company’s board leadership. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, reinforcing external oversight of Amphastar’s financial reporting.
Investors approved, on a non-binding basis, the compensation packages for the company’s named executive officers, signaling broad support for current pay practices. Stockholders further backed holding annual advisory votes on executive compensation, leading the board to commit to yearly say-on-pay votes and setting the next required vote on frequency no later than the 2032 annual meeting, which could enhance ongoing shareholder influence over governance and compensation policy.
The most recent analyst rating on (AMPH) stock is a Hold
with a $20.00 price target.
To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock,
see the AMPH Stock Forecast page.
Spark’s Take on AMPH Stock
According to Spark, TipRanks’ AI Analyst, AMPH is a Neutral.
The score is driven primarily by solid financial quality (profitability, strong cash generation, and currently low leverage). This is tempered by weak technicals (shares below major moving averages with low RSI), a relatively high P/E, and a mixed earnings update where revenue and pipeline/launch progress are offset by pronounced near-term margin and earnings pressure.
To see Spark’s full report on AMPH stock,
click here.
More about Amphastar Pharmaceuticals
Amphastar Pharmaceuticals operates in the pharmaceutical industry, developing, manufacturing, and marketing injectable and inhalation products, as well as other specialty medications, for hospital, clinical, and specialty markets. The company focuses on generics and specialty drugs, positioning itself within regulated healthcare markets where governance and shareholder oversight are significant for its strategic direction.
Average Trading Volume: 611,218
Technical Sentiment Signal: Sell
Current Market Cap: $813.5M
Find detailed analytics on AMPH stock on TipRanks’ Stock Analysis page.
